Related Experiment Video
Updated: Mar 16, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
Yoojoo Lim1, Jeong Ok Lee1, Soo Mee Bang2
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Insights
This study presents the first Korean nationwide statistics for myeloproliferative neoplasms (MPN), revealing increasing incidence and prevalence of polycythemia vera (PV), myelofibrosis (MF), and essential thrombocythemia (ET). MF showed the lowest survival rate.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Nationwide statistical data on classical myeloproliferative neoplasms (MPN) in Korea were previously unavailable.
- Understanding the epidemiology of MPN is crucial for public health planning and resource allocation.
Purpose of the Study:
- To analyze the incidence, survival rates, and treatment patterns of polycythemia vera (PV), primary myelofibrosis (MF), and essential thrombocythemia (ET) in Korea.
- To establish the first comprehensive Korean nationwide statistics for MPN.
Main Methods:
- Utilized the Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database.
- Analyzed data from 2003 to 2011, covering 4,342 new MPN cases.
- Calculated crude incidence rates, five-year relative survival rates, and treatment patterns.
Main Results:
- Essential thrombocythemia (ET) was the most common MPN, followed by MF and PV.
- Crude incidence rates for PV, MF, and ET increased from 2003-2011.
- The five-year relative survival rate for all MPN was 89.3%, with MF having the lowest at 53.1%.
- Hydroxyurea prescription rates were higher in patients over 60.
Conclusions:
- This study provides the first Korean nationwide statistics for MPN, essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF).
- Findings indicate increasing trends in MPN incidence and prevalence, with significant survival disparities among subtypes.
- The data can inform international comparisons and guide clinical guidelines.
Abstract:
The nationwide statistical analysis of each disease of classical myeloproliferative neoplasm (MPN) in Korea has not been reported yet. To this end, we have analyzed incidence rates, survival rates and treatment pattern of polycythemia vera (PV), primary myelofibrosis (MF) and essential thrombocythemia (ET) using Korea National Cancer Incidence Database (KNCIDB) and Health Insurance Review and Assessment Service (HIRA) database. Between 2003 and 2011, a total of 4,342 new cases of MPN were reported to the KNCIDB. ET was the most common, followed by MF and PV. The crude incidence rates for PV, MF, and ET have increased during the period, reaching 0.40, 0.15, and 0.84 per 100,000, respectively. Five-year relative survival rate of all MPN patients was 89.3%, with lowest relative survival rate with MF (53.1%). The prevalence of each disease estimated from HIRA data also increased during the study period. Notably, ET was found to be most prevalent. The prescription rate of hydroxyurea and phlebotomy to PV, MF and ET patients remained constant over the period, and the prescription rate of hydroxyurea was higher in patients with age over 60 years. This is the first Korean nationwide statistics of MPN, using central registry data. This set of data can be utilized to compare the Korean MPN status to international data and guidelines.
Related Concept Videos
Cancer Survival Analysis
Kaplan-Meier Approach
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Comparing the Survival Analysis of Two or More Groups
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation

